Actively Recruiting
Randomized Study Evaluating Dermial40 mg for Enhancing Skin Radiance and Reducing Facial Aging Signs in Healthy Women Aged 35 to 65
Led by Bioiberica · Updated on 2026-09-18
146
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of Dermial40 mg daily on skin brightness, hydration, and other signs of facial skin aging in healthy women aged 35 to 65 years with normal age-related skin changes. This randomized, double-blind, placebo-controlled study aims to compare Dermial40 mg with a placebo over a 12-week period to assess its influence on facial skin brightness and aging signs. Participants will be assigned randomly to receive either Dermial40 mg per day or a placebo for 12 weeks. The study includes assessments at baseline, 3 weeks, 6 weeks, and 12 weeks, involving instrumental skin measurements, standardized facial photography, investigator evaluations, and participant questionnaires to evaluate skin brightness, hydration, pH, wrinkles, roughness, scaling, smoothness, and overall facial aging. Participants will attend study visits at the four assessment points where safety and tolerability will be monitored by tracking adverse events and treatment compliance. Researchers will measure changes in facial skin glow primarily in the crows feet area, as well as secondary outcomes including skin radiance, hydration, pH, and participant satisfaction. The total participation lasts 12 weeks, with continuous safety evaluation throughout.
CONDITIONS
Brief Title
Clinical Study to Evaluate the Anti-aging Efficacy and Skin Radiance-enhancing Effect of Dermial®.
Research Team
P
Patricia Gálvez Martín, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here